William J. Boyle

Warburg Pincus LLC (Warburg Pincus) is a private equity subsidiary of Warburg Pincus & Company US LLC founded in 1966. The firm is headquartered in New York.

Paulson & Co., Inc. (PCI) is an independent hedge fund management firm headquartered in New York City. The firm was founded by John Paulson in 1994. PCI provides services to investment vehicle pools and manages accounts for banking institutions, corporations and pension and profit-sharing plans.

HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Wildcat Discovery Technologies, Inc. provides commercial research and development services. The firm engages in development projects for materials for other applications, including gas storage, carbon capture, thermoelectric, and structural materials. Its products include electrolyte additives such as EM1, CM1, CM2, and EM2. The company was founded by Peter G. Schultz and Robert K. Downs in 2006 and is headquartered in San Diego, CA.

Inventure Renewables, Inc. provides process technologies for the extraction of mixed sugars and other value-added derivatives. It offers biofuels, biochemicals and biomaterials solurions. The company was founded by Hans Haglund and Mark G. Tegen in July 2007 and is headquartered in Tuscaloosa, AL.

Renetx Bio, Inc. operates as a biotechnology company that develops disease modifying therapeutics. It offers Nogo Receptor and Cellular Prion Protein technology. The company was founded by Sylvia McBrinn and Stephen Strittmatter in 2009 and is headquartered in New Haven, CT.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

University of Washington functions as a College/University. The company is headquartered in Seattle, WA.

Presidio Partners is a venture capital firm founded in the year 1989 by Thomas R. Baruch. The firm is headquartered in San Francisco, California.

Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.

Cell Signaling Technology, Inc. manufactures and distributes research tools for cell function and diseases. It offers primary antibodies, activators and inhibitors, buffers and dyes, cellsimple, and cytokines. The company was founded in 1999 and is headquartered in Danvers, MA.

Fred Hutchinson Cancer Research Center is a non-profit organization which provides research and testing services. The company was founded in 1965 and is headquartered in Seattle, WA.

New England Biolabs, Inc. produces and supplies reagents for the life science industry. The firm?s products include restriction endonucleases, PCR, qPCR and amplification technologies, DNA modifying enzymes, sample preparation for next generation sequencing, nucleic acid purification, DNA assembly, cloning and mutagenesis kits, genome editing, competent cells, markers and ladders, RNA reagents, gene expression, cellular analysis, epigenetics, protein tools, DNA plasmids, glycobiology, protein expression and purification technologies. The company was founded by Donald Comb in 1974 and is headquartered in Ipswich, MA.

Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ.

Basic Supply Co., Inc. engages in the distribution of school and office supplies. The company was founded on November 15, 1977 and is headquartered in Huntington, WV.

Shumway Capital Management LLC (Shumway Capital) is a private equity and venture capital firm founded in 2001 by Chris Shumway. The firm is headquartered in Greenwich, Connecticut.

Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA.

Part of HBM Partners AG, HBM Healthcare Investments (Cayman) Ltd. provides healthcare services. The company is based in George Town, Cayman Islands. Andreas Wicki has been the CEO of the company since 2001.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

Soleus Capital Management LP (Soleus Capital) is a private equity subsidiary of Soleus GP LLC founded in 2018. The firm is headquartered in Greenwich, Connecticut.

Symvivo Corp. is a Canadian clinical-stage biotechnology company that specializes in advancing therapeutics in the area of oral DNA vaccines, oncology, immunology, and gene replacement. The private company's Bactrl platform technology delivers plasmid DNA, both orally and through IV application, that enables a patient's own cells to produce therapeutic proteins. Symvivo is headquartered in Burnaby, Canada. The company was founded by Alexander Graves, who has been the CEO since incorporation.

Soleus Capital Management LP (Investment Management) (Soleus Capital-IM) is the investment management division of Soleus Capital Management LP, a private equity firm headquartered in Greenwich, Connecticut. The firm is ultimately held by Soleus GP LLC. Soleus Capital-IM provides investment advisory services to privately offered pooled investment funds.

Mahzi Therapeutics is a private biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. The company was founded by Yael Weiss and is based in San Mateo, CA. The company unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi's team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases. Yael Weiss has been the CEO since incorporation.

Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang.

AdrenoMed AG develops a drug to decrease mortality in severe sepsis. The company was founded by Bernd Wegener, Gerald Heinz Möller and Andreas Bergmann in 2009 and is headquartered in Berlin, Germany.